Sign in

Sarah Ackley

@sfackley.bsky.social
650 followers 1.3K following 87 posts

Assistant Professor of Epidemiology at Brown University. Dementia Pharmacoepidemiology. Dynamical Modeling. Statistics. Metascience & Knowledge Representation. Cat Mom. She/her.

PostsRepliesMedia
Reposted by Sarah Ackley
MedPage Today @medpagetoday.com · 23/05/2026
A statistical approach used to support amyloid-targeting treatment for Alzheimer's disease may lead to overstated claims about amyloid-cognition relationships, an analysis suggested. @sfackley.bsky.social www.medpagetoday.com/neurology/alzh…
medpagetoday.com
Study Questions Methods Used in Alzheimer's Drug Analysis
Quantile aggregation may lead to overstated claims about amyloid-cognition relationships
081
Sarah Ackley @sfackley.bsky.social · 22/05/2026
Check out our new research letter!
081
Reposted by Sarah Ackley
Mike Greicius @mikegreicius.bsky.social · 18/05/2026
🧪 #alzheimer #amyloid Amazing new paper from @sfackley.bsky.social that exposes the statistical alchemy Lilly applied to their donanemab data: jamanetwork.com/journals/jam... There is little to no correlation between amyoid removal and clinical outcomes with donanemab (or lecanemab).
jamanetwork.com
Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials
This study evaluates the quantile-aggregation method using both simulated data and publicly available Alzheimer disease randomized trial data.
1227
Reposted by Sarah Ackley
Isabel Elaine Allen @datacooker.bsky.social · 18/05/2026
Beware the reanalysis -
052
Reposted by Sarah Ackley
AcadeMax @academaxjournals.bsky.social · 18/05/2026
Appreciation to @mikegreicius.bsky.social for sharing this and to @sfackley.bsky.social for this important paper. It carefully examines whether amyloid removal in donanemab aligns with meaningful clinical benefit. Follow @academaxjournals.bsky.social for relevant research. #Science #Neuroscience
071
Reposted by Sarah Ackley
Brown University School of Public Health @brownpublichealth.bsky.social · 18/05/2026
Professor @sfackley.bsky.social finds prior methods of studying cognition and amyloid, which builds up in the brains of Alzheimer’s patients "made a failed trial look like it had successfully removed amyloid." Learn more 🧠 sph.brown.edu/news/2026-05-18/alzhe…
Visualization of brain neurons coated in amyloid protein, a feature of Alzheimer's disease.Smiling headshot of Professor Sarah Ackley
051
Reposted by Sarah Ackley
Mike Greicius @mikegreicius.bsky.social · 18/05/2026
Lilly used "quantile-aggregation" to transform individual level data with 100s of data points and a correlation of 0.08 (see figure) into 10 data points with a correlation of 0.87! Dr. Ackley clearly debunks this approach with simulations and real-world data. Check it out. Spread the word.
A scatter plot showing the minimal correlation between amyloid removal and clinical outcomes in the phase 3 trial for donanemab. R-squared is less than 1% (meaning less than 1% of the variance in the clinical measure can be explained by the amyloid removal).
051
Sarah Ackley @sfackley.bsky.social · 18/05/2026
Eli Lilly’s reanalysis of TRAILBLAZER-ALZ 2 proposes a new method for evaluating amyloid as a surrogate endpoint and argues the resulting high R-squared values are “unlikely to be artificially inflated.” Our response now out in JAMA Neurology: they are. jamanetwork.com/journals/jam...
jamanetwork.com
Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials
This study evaluates the quantile-aggregation method using both simulated data and publicly available Alzheimer disease randomized trial data.
041
Reposted by Sarah Ackley
Washington Post Opinions @postopinions.bsky.social · 28/02/2026
"I am a clinical epidemiologist whose research focuses on assessing interventions for the treatment and prevention of dementia," @sfackley.bsky.social writes. "I believe it is premature to promote coffee for the prevention of dementia." wapo.st/4s5WRiD
051
Reposted by Sarah Ackley
Alt The National Institute on Aging @altthenia.bsky.social · 06/11/2025
For those of you attending #GSA2025 in Boston, consider this panel of #NIH awardees, Drs. Alden Gross, @mariaglymour.bsky.social , @sfackley.bsky.social , and @bryandjames.bsky.social. Please remember to tag #geronsky and @geronsociety.bsky.social in your posts.
The "biggest baddest" bias in aging research: A spirited GSA debate.
0157
Reposted by Sarah Ackley
Alzheimer's & Dementia Journals @alzdemjournals.bsky.social · 03/11/2025
🔔 #TRCI Special Issue 🔔 Marking the 10th anniversary of AD Drug Development Pipeline articles led by Dr. Jeffrey Cummings! Submit your research highlighting advances in ADRD clinical trials and drug development! ⏰Oct. 31, 2026 alz-journals.onlinelibrary.wiley.com/hub/journal/...
alz-journals.onlinelibrary.wiley.com
Alzheimer's & Dementia: Translational Research & Clinical Interventions
<em>Alzheimer's & Dementia: Translational Research & Clinical Interventions</em> journal bridges drug discovery research and clinical studies for dementia & Alzheimer's.
163
Reposted by Sarah Ackley
Maria Glymour @mariaglymour.bsky.social · 14/09/2025
Such a cool paper. #EpiSky @amjepi.bsky.social #DataScience #Reproducibility Led by @sfackley.bsky.social at @brown-epi.bsky.social Research on reproducible research funded by NIH/NIA - thank you!
0102
Sarah Ackley @sfackley.bsky.social · 28/08/2025
Check out our recently published paper at AJE! academic.oup.com/aje/advance-... We analyzed 21,332 abstracts (2000-2024) from four major epidemiology journals, extracting 25,288 P values using ChatGPT’s 4o model with few-shot in-context prompting. #episky #reproducibility #metasci #metascience
academic.oup.com
Validate User
152
Reposted by Sarah Ackley
Triangulation of Innovative Methods to End Alzheimer’s Disease @timead.bsky.social · 25/07/2025
#TIME-AD is heading to #AAIC25! 📊 We’ll be sharing results from our latest preprint examining whether reductions in brain amyloid—a key Alzheimer’s biomarker—can meaningfully predict changes in cognition and functioning. 🔗 Read the preprint: tinyurl.com/5n8psura
021
Sarah Ackley @sfackley.bsky.social · 25/07/2025
Looking forward to presenting this renanalysis of the A4 study, as well as a simulation study evaluating SILA's ability to detect ceilings in amyloid accumulation at #AAIC25. #ENDALZ www.medrxiv.org/content/10.1...
medrxiv.org
Evaluation of Amyloid Removal as a Surrogate for Cognitive Decline: Pilot Analysis in Individual-Level Data from the A4 Study of Solanezumab
Background Amyloid removal has been used as a surrogate outcome in Alzheimer’s disease trials, allowing accelerated approval of aducanumab and lecanemab. The A4 (Alzheimer’s Clinical Trial Consortium ...
020
Reposted by Sarah Ackley
Triangulation of Innovative Methods to End Alzheimer’s Disease @timead.bsky.social · 23/07/2025
🧠 TIME-AD is now on Bluesky! #TIME-AD brings together results from different study designs and populations to find what really works to prevent and delay dementia. Follow along as we share what we’re learning and check out our website to learn more: www.time-ad.org #EndALZ #EpiSky #NeuroSky
195
Sarah Ackley @sfackley.bsky.social · 22/07/2025
New preprint up! Evaluation of Amyloid Removal as a Surrogate for Cognitive Decline: Pilot Analysis in Individual-Level Data from the A4 Study of Solanezumab www.medrxiv.org/content/10.1...
medrxiv.org
131
Reposted by Sarah Ackley
Andrea Gilmore Bykovskyi @algilmore.bsky.social · 25/06/2025
Excellent talk at #MELODEM2025 by @sfackley.bsky.social evaluating amyloid as a surrogate marker with individual level A4 trial data One big take away — 5 years was not enough time to see cognitive decline in the placebo group == a major challenge
121
Reposted by Sarah Ackley
Jennifer Weuve @epidancer.bsky.social · 25/06/2025
Now at #MELODEM2025 Is reducing/removing amyloid from the brain a reasonable surrogate for slowing/stopping cognitive decline in dementia? @sfackley.bsky.social uses data from the A4 RCT (of solanezumab) to answer this q, ... @melodem.bsky.social
131
Sarah Ackley @sfackley.bsky.social · 27/05/2025
I was invited to comment for AlzForum on GLP-1s and dementia. GLP-1s show promise, but RCTs like GRADE have not demonstrated clear cognitive benefits. Observational studies may be confounded by socioeconomic factors and prescribing patterns. Read the full comment: www.alzforum.org/papers/gluco...
alzforum.org
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial. | ALZFORUM
020
Sarah Ackley @sfackley.bsky.social · 24/04/2025
In addition to today's NIH-grant-related anxiety, a cat vomited a fur ball in my shoe.
020
Sarah Ackley @sfackley.bsky.social · 15/04/2025
www.nytimes.com/2025/04/14/u...
nytimes.com
Harvard Will Not Comply With a List of Trump Administration Demands (Gift Article)
Federal officials said Harvard must enact “merit-based reform” in hiring and admissions and report international students who broke rules, among other steps. Harvard called the demands unlawful.
120
Sarah Ackley @sfackley.bsky.social · 14/04/2025
I wrote 1/3 of a page of my grant!
headings only: significance, innovation, approach, future directions
120
Sarah Ackley @sfackley.bsky.social · 07/04/2025
So many more people than I realized!
010
Sarah Ackley @sfackley.bsky.social · 06/04/2025
Note on my previous calculation--arguably 1/1000 is too high.
010
Sarah Ackley @sfackley.bsky.social · 06/04/2025
1/ The number of deaths (3) in this measles outbreak seems high given its size (480 TX + 50 OK + 10 NM = 544). Typically, ~1/1000 die from measles based on past data (pre- and post-elimination). Is it possible cases are underreported? #episky
242
Sarah Ackley @sfackley.bsky.social · 05/04/2025
Some math/physics history I happened across yesterday— David Hilbert lived to see the Nazis purge many prominent faculty members at the University of Göttingen in 1933, including Hermann Weyl, Emmy Noether, and Edmund Landau. (Wikipedia)
110
Reposted by Sarah Ackley
The New York Times @nytimes.com · 03/04/2025
Breaking News: The Trump administration intends to block $510 million in federal contracts and grants for Brown University.
nytimes.com
Trump Administration Set to Pause $510 Million for Brown University
The administration has now targeted five schools’ federal funding as part of a pledge to combat what it considers to be antisemitism on university campuses.
103473269
Sarah Ackley @sfackley.bsky.social · 02/04/2025
Of all the important questions and issues raised here, the least pressing (but still curious) is... why is the thumbnail a photo of MIT? www.msn.com/en-us/news/p...
msn.com
MSN
110
Sarah Ackley @sfackley.bsky.social · 26/03/2025
Hmmm… This must be why my work backpack is always covered in cat fur
020
Sarah Ackley @sfackley.bsky.social · 12/03/2025
Science, Anti-Science, Pseudoscience, Truth--very timely & relevant themes in this excerpt on Feyerabend. Fascinating read. Some general + epi-specific thoughts: 🔗 www.thephilosopher1923.org/post/pseudos...
thephilosopher1923.org
"Pseudoscience after Feyerabend": Chiara Ambrosio and Ian James Kidd (Keywords: Epistemology; Objectivity; Science; Authority; Astrology)
"The criteria we use to discuss science and pseudoscience are incredibly context dependent."
112
Sarah Ackley @sfackley.bsky.social · 07/03/2025
Stand Up for Science in Providence!
0215
Sarah Ackley @sfackley.bsky.social · 26/02/2025
Struggling to compare treatment effects across different cognitive measures? Check out our new paper. alz-journals.onlinelibrary.wiley.com/doi/full/10....
alz-journals.onlinelibrary.wiley.com
Methods to crosswalk between cognitive test scores using data from the Alzheimer's Disease Neuroimaging Cohort
INTRODUCTION Studies use multiple different instruments to measure dementia-related outcomes, making head-to-head comparisons of interventions difficult. METHODS To address this gap, we developed ...
062
Sarah Ackley @sfackley.bsky.social · 22/02/2025
A couple thoughts on Piller's piece that didn't fit in my letter. First: Anti-amyloid treatments appear to cause brain shrinkage-- this is definitely a concern. But we don't actually know if it's bad and there's reason to think it might not be. We need individual-level data to know for sure!
140
Reposted by Sarah Ackley
Maria Glymour @mariaglymour.bsky.social · 22/02/2025
Amidst the "amyloid mafia" debate, Sarah Ackley chimes in with a concrete proposal that would very quickly deliver better evidence on how to treat Alzheimer's disease and the promise of anti-amyloid therapies: the companies should share the data for combined, individual-level analyses.
2113
Sarah Ackley @sfackley.bsky.social · 22/02/2025
Check out my letter on amyloid-targeting drugs in STAT! www.statnews.com/2025/02/22/l... A thread #episky
statnews.com
Is there an amyloid mafia? STAT readers weigh in
“Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to the editor this week.
184
Sarah Ackley @sfackley.bsky.social · 14/02/2025
www.medrxiv.org/content/10.1... Have efforts from epidemiologists to reduce reliance on P values reduced P hacking? Probably not. Do decreases in the fraction of P values just below 0.05 necessarily imply less P hacking? No. #episky #metascience
medrxiv.org
Trends in the Distribution of P Values in Epidemiology Journals: Decreased P Hacking or Increased Power?
Epidemiologists have advocated for reporting confidence intervals and deemphasizing P values to address long-standing concerns about null-hypothesis statistical-significance testing, P hacking, and re...
194
Sarah Ackley @sfackley.bsky.social · 14/02/2025
I know there's not much good news, but I have a big win! For the first time in my research career, I submitted a paper, and it went straight to review without (multiple rounds) of formatting corrections!
180
Sarah Ackley @sfackley.bsky.social · 24/12/2023
I'd like to know what these tests and treatments are. 🤨
Apple News: The Dementia Advancements Offering New Hope
After decades of frustration, researchers have finally developed effects tests and treatments for cognitive decline.
220
Sarah Ackley @sfackley.bsky.social · 24/11/2023
Thanksgiving!!!!!
A plate of thanksgiving food with mashed potatoes, green beans, squash, salad, and faux-turkey with gravy
040